Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
Authors
Keywords
Peroxisome proliferator-activated receptor, Fibrate, SPPARM, K-877, Cardiovascular, Diabetes, Metabolic syndrome
Journal
Cardiovascular Diabetology
Volume 12, Issue 1, Pages 82
Publisher
Springer Nature
Online
2013-05-31
DOI
10.1186/1475-2840-12-82
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Modulating peroxisome proliferator–activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects
- (2012) Robert S. Rosenson et al. AMERICAN HEART JOURNAL
- Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
- (2012) Alexander Tenenbaum et al. Cardiovascular Diabetology
- Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes
- (2012) Kwok Leung Ong et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
- (2012) Anette Varbo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- FGF21 Takes a Fat Bite
- (2012) C. Canto et al. SCIENCE
- Effects of the New Dual PPAR / Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
- (2011) B. Cariou et al. DIABETES CARE
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
- (2011) M. John Chapman et al. EUROPEAN HEART JOURNAL
- Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk
- (2011) Lisa M Younk et al. Expert Opinion on Drug Metabolism & Toxicology
- The contrasting roles of PPARδ and PPARγ in regulating the metabolic switch between oxidation and storage of fats in white adipose tissue
- (2011) Lee D Roberts et al. GENOME BIOLOGY
- Estudio REALIST (REsiduAl risk, LIpids and Standard Therapies): Un análisis del Riesgo Residual dependiente del perfil lipídico en el síndrome coronario agudo
- (2011) Jesús Millán Núñez-Cortés et al. Endocrinologia y Nutricion
- Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control
- (2010) Vincent J. Carey et al. AMERICAN JOURNAL OF CARDIOLOGY
- Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
- (2010) T. M. E. Davis et al. DIABETOLOGIA
- Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents
- (2010) Lalit S Doshi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Effects of high dose aleglitazar on renal function in patients with type 2 diabetes
- (2010) Matthias Herz et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Selective peroxisome proliferator-activated receptor γ (PPARγ) modulation as a strategy for safer therapeutic PPARγ activation
- (2009) Linda Slanec Higgins et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease
- (2009) Jean-Charles Fruchart ATHEROSCLEROSIS
- Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
- (2009) Robert R Henry et al. LANCET
- Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
- (2009) Kushwin Rajamani et al. LANCET
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now